Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Kynurenine and uric acid levels in chronic myeloid leukemia patients

Vonka V, Humlova Z, Klamova H, Kujovska-Krcmova L, Petrackova M, Hamsikova E, Krmencikova-Fliegl M, Duskova M, Roth Z

. 2015 ; 4 (3) : e992646.

Jazyk angličtina Země Spojené státy americké

Perzistentní odkaz   https://www.medvik.cz/link/bmc19036784

Grantová podpora
NT12363 MZ0 CEP - Centrální evidence projektů

Indoleamine 2,3-dioxygenase 1 (IDO1), IDO2 and tryptophan 2,3-dioxygenase (TDO) represent some of the key immune regulators. Their increased activity has been demonstrated in a number of human malignancies but not yet in chronic myeloid leukemia (CML). In the present study, the activity of these enzymes was tested in 29 CML patients and 28 healthy subjects by monitoring the kynurenine (KYN)/tryptophan ratio. Serum samples taken prior to the therapy displayed a highly significant difference in KYN levels between the patient and control groups. However, increased KYN levels were detected in only 13 (44.8%) of these CML patients. The KYN levels in pretreatment sera of the patients correlated with the tumor burden. There was also a strong correlation between KYN levels and uric acid levels (UA). This suggests but does not prove the possible involvement of UA in activating IDO family of enzymes. Whenever tested, the increased KYN levels normalized in the course of the therapy. Patients with normal KYN levels in their pretreatment sera and subsequently treated with interferon-α, showed a transitory increase in their KYN levels. The present data indicate that CML should be added to the malignancies with an increased activity of the IDO family of enzymes and suggest that IDO inhibitors may be used in the treatment of CML patients.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc19036784
003      
CZ-PrNML
005      
20191213144325.0
007      
ta
008      
191015s2015 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.4161/2162402x.2014.992646 $2 doi
035    __
$a (Pubmed)25949913
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Vonka, Vladimír, $d 1930- $7 jk01150642 $u Department of Experimental Virology; Institute of Haematology and Blood Transfusion ; Prague, Czech Republic
245    10
$a Kynurenine and uric acid levels in chronic myeloid leukemia patients / $c Vonka V, Humlova Z, Klamova H, Kujovska-Krcmova L, Petrackova M, Hamsikova E, Krmencikova-Fliegl M, Duskova M, Roth Z
520    9_
$a Indoleamine 2,3-dioxygenase 1 (IDO1), IDO2 and tryptophan 2,3-dioxygenase (TDO) represent some of the key immune regulators. Their increased activity has been demonstrated in a number of human malignancies but not yet in chronic myeloid leukemia (CML). In the present study, the activity of these enzymes was tested in 29 CML patients and 28 healthy subjects by monitoring the kynurenine (KYN)/tryptophan ratio. Serum samples taken prior to the therapy displayed a highly significant difference in KYN levels between the patient and control groups. However, increased KYN levels were detected in only 13 (44.8%) of these CML patients. The KYN levels in pretreatment sera of the patients correlated with the tumor burden. There was also a strong correlation between KYN levels and uric acid levels (UA). This suggests but does not prove the possible involvement of UA in activating IDO family of enzymes. Whenever tested, the increased KYN levels normalized in the course of the therapy. Patients with normal KYN levels in their pretreatment sera and subsequently treated with interferon-α, showed a transitory increase in their KYN levels. The present data indicate that CML should be added to the malignancies with an increased activity of the IDO family of enzymes and suggest that IDO inhibitors may be used in the treatment of CML patients.
650    12
$a chronická myeloidní leukemie $7 D015464
650    12
$a kynurenin $x krev $7 D007737
650    12
$a tryptofan $x krev $7 D014364
650    _2
$a biologické markery $x krev $7 D015415
650    12
$a kyselina močová $7 D014527
650    _2
$a indolamin-2,3,-dioxygenasa $7 D050503
650    _2
$a dospělí $7 D000328
650    _2
$a lidé $7 D006801
650    _2
$a lidé středního věku $7 D008875
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a senioři $7 D000368
650    _2
$a ženské pohlaví $7 D005260
700    1_
$a Humlová, Zuzana, $d 1973- $7 xx0014342 $u Institute of Immunology; First Medical Faculty; Charles University ; Prague; Czech Republic ; Department of Immunology and Microbiology; 1st Medical Faculty; Charles University, and the General Teaching Hospital in Prague ; Prague, Czech Republic
700    1_
$a Klamová, Hana $7 xx0081721 $u Department of Experimental Virology; Institute of Haematology and Blood Transfusion ; Prague, Czech Republic
700    1_
$a Krčmová Kujovská, Lenka, $d 1981- $7 xx0209338 $u Department of Analytical Chemistry; Faculty of Pharmacy; Charles University ; Hradec Králové, Czech Republic ; III. Internal Gerontometabolic Clinic; University Hospital ; Hradec Králové, Czech Republic
700    1_
$a Petráčková, Martina $7 xx0086591 $u Department of Experimental Virology; Institute of Haematology and Blood Transfusion ; Prague, Czech Republic
700    1_
$a Hamšíková, Eva $7 xx0052821 $u Department of Experimental Virology; Institute of Haematology and Blood Transfusion ; Prague, Czech Republic
700    1_
$a Fliegl, Monika $7 xx0212897 $u Department of Experimental Virology; Institute of Haematology and Blood Transfusion ; Prague, Czech Republic
700    1_
$a Dušková, Martina $7 xx0127833 $u Department of Experimental Virology; Institute of Haematology and Blood Transfusion ; Prague, Czech Republic
700    1_
$a Roth, Zdeněk, $d 1930-2015 $7 xx0110852 $u Department of Biostatistics; State Institute of Health ; Prague, Czech Republic
773    0_
$t Oncoimmunology $x 2162-4011 $g Roč. 4, č. 3 (2015), s. e992646 $w MED00190079
910    __
$a ABA008 $b sig $y p $z 0
990    __
$a 20191015104550 $b ABA008
991    __
$a 20191213144626 $b ABA008
999    __
$a ok $b bmc $g 1454942 $s 1075351
BAS    __
$a 3
BMC    __
$a 2015 $b 4 $c 3 $d e992646 $x MED00190079 $i 2162-4011 $m Oncoimmunology
GRA    __
$a NT12363 $p MZ0
LZP    __
$a NLK 2019/lp

Najít záznam

Citační ukazatele

Možnosti archivace